Quick Answer
ALX ONCOLOGY HOLDINGS INC reported Stockholders Equity of $25.98 million for fiscal year 2025.
ALX ONCOLOGY HOLDINGS INC Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $25.98M | -77.1% |
| 2024 | $113.62M | -40.1% |
| 2023 | $189.71M | -28.0% |
| 2022 | $263.46M | -27.4% |
| 2021 | $363.05M | -15.5% |
| 2020 | $429.85M | +708.5% |
| 2019 | -$70.64M | -36.4% |
| 2018 | -$51.78M | -34.8% |
| 2017 | -$38.41M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $44.80M | -67.3% | -30.5% |
| June 30, 2025 | $64.42M | -59.6% | -27.0% |
| March 31, 2025 | $88.30M | -46.2% | -22.3% |
| December 31, 2024 | $113.62M | -40.1% | -17.0% |
| September 30, 2024 | $136.81M | -18.9% | -14.1% |
| June 30, 2024 | $159.32M | -25.1% | -3.0% |
| March 31, 2024 | $164.19M | -31.7% | -13.5% |
| December 31, 2023 | $189.71M | -28.0% | +12.4% |
- ALX ONCOLOGY HOLDINGS INC showed a decrease of -77.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2025 period, ALX ONCOLOGY HOLDINGS INC’s stockholders equity has grown by 167.6% (from -$38.41 million to $25.98 million).
- The most recent figure is from ALX ONCOLOGY HOLDINGS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: